Skip to main content


  • Research
  • Open Access

Long-term lithium treatment in bipolar disorder: effects on glomerular filtration rate and other metabolic parameters

  • 1, 2, 3Email author,
  • 4,
  • 5,
  • 6,
  • 7, 8,
  • 9,
  • 5,
  • 8,
  • 10,
  • 11, 12,
  • 13,
  • 10,
  • 14,
  • 3, 15,
  • 14,
  • 3,
  • 16,
  • 6,
  • 4,
  • 17,
  • 19,
  • 1, 9,
  • 17, 18,
  • 2, 20, 21,
  • 16,
  • 10 and
  • 1, 2
International Journal of Bipolar Disorders20175:27

  • Received: 9 December 2016
  • Accepted: 18 April 2017
  • Published:



Concerns about potential adverse effects of long-term exposure to lithium as a mood-stabilizing treatment notably include altered renal function. However, the incidence of severe renal dysfunction; rate of decline over time; effects of lithium dose, serum concentration, and duration of treatment; relative effects of lithium exposure vs. aging; and contributions of sex and other factors all remain unclear.


Accordingly, we acquired data from 12 collaborating international sites and 312 bipolar disorder patients (6142 person-years, 2669 assays) treated with lithium carbonate for 8–48 (mean 18) years and aged 20–89 (mean 56) years. We evaluated changes of estimated glomerular filtration rate (eGFR) as well as serum creatinine, urea–nitrogen, and glucose concentrations, white blood cell count, and body-mass index, and tested associations of eGFR with selected factors, using standard bivariate contrasts and regression modeling.


Overall, 29.5% of subjects experienced at least one low value of eGFR (<60 mL/min/1.73 m2), most after ≥15 years of treatment and age > 55; risk of ≥2 low values was 18.1%; none experienced end-stage renal failure. eGFR declined by 0.71%/year of age and 0.92%/year of treatment, both by 19% more among women than men. Mean serum creatinine increased from 0.87 to 1.17 mg/dL, BUN from 23.7 to 33.1 mg/dL, glucose from 88 to 122 mg/dL, and BMI from 25.9 to 26.6 kg/m2. By multivariate regression, risk factors for declining eGFR ranked: longer lithium treatment, lower lithium dose, higher serum lithium concentration, older age, and medical comorbidity. Later low eGFR was also predicted by lower initial eGFR, and starting lithium at age ≥ 40 years.


Control data for age-matched subjects not exposed to lithium were lacking.


Long-term lithium treatment was associated with gradual decline of renal functioning (eGFR) by about 30% more than that was associated with aging alone. Risk of subnormal eGFR was from 18.1% (≥2 low values) to 29.5% (≥1 low value), requiring about 30 years of exposure. Additional risk factors for low eGFR were higher serum lithium level, longer lithium treatment, lower initial eGFR, and medical comorbidity, as well as older age.


  • Blood urea nitrogen
  • Body-mass index
  • Creatinine
  • eGFR
  • Glomerular filtration rate
  • Glucose
  • Lithium
  • Staging of renal function
  • White blood cell count


Decades of widespread international clinical use of lithium salts with controlled dosing, as well as extensive therapeutic research, support the value of lithium as a cornerstone of long-term, prophylactic treatment of patients diagnosed with bipolar disorder (Bauer et al. 2006; Baldessarini 2013; Severus et al. 2014; Bauer and Gitlin 2016). Nevertheless, an adverse effect of major concern associated with long-term lithium treatment is the risk of developing chronic kidney disease (CKD). This outcome usually is defined as a decrease of glomerular filtration rate (GFR) to <60 mL/min per 1.73 m2 observed at least twice in not less than 3 months (Azab et al. 2015). Severe loss of renal function and end-stage renal disease (ESRD) are uncommon with lithium treatment, with a prevalence of approximately 1.5%, but 7-folds higher than the general population (Aiff et al. 2015). Risk of renal dysfunction is believed to be associated with longer exposure to lithium as well as with advancing age with or without lithium, and appears to have changed little over the recent decades (Aiff et al. 2015; Jonczyk-Potoczna et al. 2016). Pathological renal changes associated with long exposure to lithium in clinical doses have included the presence of macrocysts, microcysts, glomerulosclerosis, proximal tubular atrophy, and chronic interstitial fibrosis (Albrecht et al. 1980; Oliveira et al. 2010; Alsady et al. 2016; Jonczyk-Potoczna et al. 2016). Molecular mechanisms associated with such dysfunction appear to be multiple and complex. Based mainly on preclinical models, they include alterations in calcium signaling, inositol monophosphate and phosphodiesterase activities, prostaglandins, sodium-solute transport, G-protein-coupled receptors, nitric oxide, vasopressin aquaporin, and inflammation pathways (Rej et al. 2016). However, it is unclear why only some patients develop nephropathy in association with lithium treatment, regardless of age or lithium exposure.

At least 20 findings related to renal dysfunction have emerged from studies of patients treated long term with lithium (Azab et al. 2015). They include (Table 1) (a) significant increase of serum creatinine concentration, not associated with age, in 99 lithium-treated patients followed for up to 10 years (Depaulo et al. 1981); (b) no difference in eGFR among 30 patients aged 55, treated with lithium for 6.2 years and 30 others not exposed to lithium (Hullin et al. 1979); (c) no difference in eGFR among 32 patients aged 49 years, treated with lithium for 5.7 years and 32 matched controls (Bendz 1985); (d) more prevalent low eGFR in 13 patients (mean age, 59 years) treated with lithium for 18 years (5/13) than that in 13 matched controls never exposed to lithium (0/13; χ 2 = 6.19, p = 0.01) (Bendz et al. 1996); (e) no difference in eGFR in 107 patients aged 39 treated with lithium for 4.5 years (eGFR = 86.5 [CI 82.4–90.6]) compared with 29 matched controls (83.9 [76.1–91.7] units) (Coşkunol et al. 1997); (f) lower eGFR among 10 patients/group of average age 35, exposed to lithium for 6.7 years (72.8 [50.7–94.9]) compared to those exposed for 1.3 years (150 [129–172]) or no exposure (125 [112–138] units) (Turan et al. 2002); (g) a risk of ESRD of 0.53% among 3369 subjects of average age 65 exposed to lithium for 23 years, compared to 0.082% of the general Swedish population—a 6.5-fold difference (χ 2 = 82.5, p < 0.0001) (Bendz et al. 2010); (h) eGFR < 60 units in 23.0% of 80 patients treated with lithium up to 38 (mean, 17) years, and more often among men (38%) than women (16%; p = 0.04) (Rybakowski et al. 2012); (i) eGFR values were lower in 27.3% of 139 lithium-treated patients of mean age 54, exposed to lithium for ≥1 year, compared to 5.71% among 70 psychiatric controls—a difference of 4.8-fold (χ 2 = 9.66, p < 0.002), and were more likely among older patients and men (Bocchetta et al. 2013); (j) mean GFR 8.0% lower among 330 general practice patients taking lithium compared with 659 matched controls, with similar prevalence of eGFR values ≤60 units in both groups (17.0 vs. 13.1%; χ 2 = 2.75, p = 0.10) (Minay et al. 2013); (k) the rate of dialysis treatment or renal transplantation in the Swedish general population was 0.019%, compared to a 7.8-fold higher rate of 1.5% among 1995 lithium-treated patients of age 66 years given lithium for 27 years (χ 2 = 176, p < 0.0001) (Aiff et al. 2014); (l) no difference in renal function in a 2-year randomized control trial (RCT) for patients given lithium >4 years (Aprahamian et al. 2014); (m) eGFR < 60 units in 12.3% of 2496 general practice patients given lithium for undefined times, compared to a 3.25-fold lower risk of 3.78% in 3864 bipolar disorder patients not given lithium, all of average age 49 (χ 2 = 165, p < 0.0001) (Close et al. 2014); (n) values of eGFR < 60 units were encountered in 32% of 630 subjects aged 66 years treated with lithium ≥10 years, and 4.5% developed ESRD (stage 4 or 5; eGFR < 30 units), with little sex-difference in either outcome (Aiff et al. 2015), (o) eGFR < 60 units was found in 12% of 953 patients given lithium for 10 years and in 50% by 25 years (Bocchetta et al. 2015); (p) no significant difference in the annual decline of eGFR in a case–control study: 305 patients aged 43 given lithium for an average of 4.6 years and 815 controls given other treatments (1.3 vs. 0.9 units) after adjustment for age, baseline eGFR, comorbidities, exposure to nephrotoxic drugs, and episodes of acute lithium toxicity (Clos et al. 2015); (q) eGFR < 60 units was 1.21-times more prevalent among 4678 lithium-treated subjects than among 689,228 controls of mean age 52 treated for up to 28 years, after adjustment for age, sex, and diabetes (estimates: 62.3 vs. 51.4%; χ 2 = 118, p < 0.0001) (Shine et al. 2015); (r) risk for eGFR < 60 units among 3850 patients, aged 54 years, treated with lithium for an average of 1.4 years was 25.7%, and was higher with multiple daily doses, higher serum concentrations, and co-treatment with first-generation neuroleptics (Castro et al. 2016); [s] eGFR < 60 units was about twofold more prevalent among 2148 lithium-treated patients than among those treated with valproate (n = 1670), olanzapine (n = 1477), or quetiapine (n = 1376) (Hayes et al. 2016); (t) in a nationwide population study, clinically diagnosed CKD was increased by up to 3.6-fold with longer exposure to lithium, and associated with use of anticonvulsants (with risk of confounding by selective avoidance of lithium with renal failure), but not antidepressants or antipsychotics (Kessing et al. 2015). To summarize, all these studies point out that lower eGFR is associated with older age and longer exposure to lithium (Table 1).
Table 1

Reports on renal effects of lithium treatment


Subjects (n)

Age (years)

Lithium exposure (years)

Main findings


No Li

Hullin et al. (1979)





No difference in eGFR

Depaulo et al. (1981)





Creatinine increased with Li

Bendz (1985)





No difference in eGFR

Bendz et al. (1996)





eGFR fell with Li

Coşkunol et al. (1997)





No difference in eGFR

Turan et al. (2002)




1.3 and 6.7

eGFR fell with long-term Li

Bendz et al. (2010)


Genl. pop.



ESRD 6.5-fold more often with Li

Rybakowski et al. (2012)





eGFR < 60: 22.5%; 2.4-times more in men

Bocchetta et al. (2013)





eGFR < 60: 4.8-fold more often with Li

Minay et al. (2013)




eGFR < 60: similar with/without Li

Aiff et al. (2014)





ESRD 7.8-fold more often with Li

Aprahamian et al. (2014)





No difference in renal function

Close et al. (2014)




eGFR < 60: 3.25-times less with Li

Aiff et al. (2015)





eGFR < 60: 32%; ESRD: 4.5-fold more with Li

Bocchetta et al. (2015)



10 and 25

eGFR < 50: 12% in 10, 50% in 25 yrs of Li

Clos et al. (2015)





No difference in eGFR

Shine et al. (2015)





eGFR < 60: 1.21-fold more often with Li

Castro et al. (2016)





eGFR < 60: 25.7% lower with multiple doses/day

Hayes et al. (2016)





eGFR < 60: ~twofold higher HR with Li

Kessing et al. (2015)

Natl. sample


Clinical CKD 3.6-times more with Li

N = 20 studies



53.1 ± 10.5

10.9 ± 8.9

Function decreased in 15/20 reports (75.0%)

Abnormal renal functioning was associated with longer exposure to lithium in these studies (15.3 ± 9.54 vs. 5.00 ± 0.91 years, respectively [t = 2.37, p = 0.035])

In addition to changes in renal functioning, the presence of macrocysts or microcysts as possible precursors of loss of kidney function has been reported in several renal-imaging studies following long-term lithium treatment (Tuazon et al. 2008; Slaughter et al. 2010; Farshchian et al. 2013; Karaosmanoglu et al. 2013; Jonczyk-Potoczna et al. 2016). Also, an increase of renal neoplasia during long-term treatment with lithium has been suggested (Zaidan et al. 2014), but not supported by other observations (Baldessarini and Tondo 2014; Licht et al. 2014; Pottegård et al. 2016).

To extend the preceding findings, we evaluated effects of lithium on GFR and other metabolic parameters in a composite sample of 312 bipolar disorder patients followed for 8–48 years in 12 international specialized mood-disorder clinics with extensive experience in the clinical use of lithium.


This international collaborative study involved data provided by 12 sites in Argentina, Canada, Germany, Italy, Poland, Spain, and Switzerland (Table 2). Subjects were adults meeting DSM-IV diagnostic criteria for bipolar I or II disorder. Participation was based on meeting local institutional requirements for the ethical conduct of research. Measurements considered included age; sex; years of exposure to lithium treatment; mean daily dose of lithium carbonate and mean daily trough serum concentration of lithium; body-mass index (BMI), white blood cell counts (WBC), and assays of serum concentrations of glucose, blood urea nitrogen (BUN), and creatinine, with estimated GFR (eGFR, in units of mL/min/1.73 m2) computed according to the chronic kidney disease (CKD)-epidemiology collaboration (CKD-EPI) formulas for Caucasian (as all study subjects were) women and men (Levey et al. 2009):
Table 2

Subject age and lithium exposure across study sites

Study site

Subjects (n)

Intake agea

Final ageb

Years on Lic

Barcelona: University of Barcelona


32.3 ± 8.06

51.8 ± 11.4

19.4 ± 7.41

Berlin: Charité Medical Center


39.5 ± 12.4

56.6 ± 14.9

17.2 ± 8.12

Buenos Aires: Palermo University


47.2 ± 12.0

62.3 ± 13.4

15.1 ± 5.93

Cagliari: Lucio Bini Mood Disorder Center


38.1 ± 12.1

54.6 ± 14.5

17.5 ± 8.61

Cagliari: University of Cagliari


37.1 ± 11.2

62.2 ± 13.1

24.1 ± 8.86

Dresden: University of Dresden


33.5 ± 12.7

53.8 ± 13.2

20.3 ± 9.49

Halifax: Dalhousie University


43.5 ± 13.7

55.4 ± 13.7

11.9 ± 3.97

Lugano: Viarnetto Clinic


33.8 ± 11.6

52.0 ± 12.9

18.2 ± 9.45

Pisa: University of Pisa


37.6 ± 13.1

49.4 ± 13.8

11.7 ± 6.29

Poznan: University of Poznan


43.1 ± 14.2

66.2 ± 10.7

23.1 ± 8.59

Rome: Lucio Bini Mood Disorder Center


36.8 ± 15.6

54.6 ± 15.9

18.4 ± 9.47

Würzburg: University of Würzburg


45.0 ± 14.9

61.8 ± 9.75

6.80 ± 7.94

Total [95% CI]


37.9 [37.5–39.3]

55.8 [54.2–57.4]

17.9 [16.9–18.9]

Total exposure = 6142 person-years

Across the 12 sites, among 312 subjects: a t = 1.55, p = 0.007; b t = 1.70, p = 0.001; c t = 1.13, p = 0.24

$${\text{females}}:{ 141} \times \left( {\left[ {\text{creatinine}} \right]/0. 7} \right)^{ - 0. 3 2 9} \times \left( {\left[ {\text{creatinine}} \right]/0. 7} \right)^{ - 1. 20 9} \times 0. 9 9 3^{\text{age}} \times 1.0 1 8;$$
$${\text{males}}:{ 141} \times \left( {\left[ {\text{creatinine}} \right]/0. 9} \right)^{ - 0. 4 1 1} \times \left( {\left[ {\text{creatinine}} \right]/0. 9} \right)^{ - 1. 20 9} \times 0. 9 9 3^{\text{age}} \times 1.0 1 8.$$

Metabolic measures at baseline were compared over times of exposure to lithium treatment, ranging from 8 to 48 years, using ANOVA methods (t-scores). Additional analyses focused on the prevalence of renal dysfunction based on low eGFR (<60 mL/min/1.73 m2), and considered standard functional staging, as: Stage 1 normal functioning (GFR  90); Stage 2 mildly decreased functioning (GFR = 6089); Stage 3 moderate dysfunction (GFR = 3059); Stage 4 severe dysfunction (GFR = 1529); and Stage 5 kidney failure (GFR < 15 or needing dialysis) (American National Kidney Foundation, NKF 2002, 2014). Low eGFR included Stages 3 and 4.

We addressed the prevalence of low values of eGFR across study sites, and changes with time and in association with selected measures, including ages (at onset, at lithium start and at the last follow up visit), sex, co-occurring medical illnesses, and exposure to lithium (by daily dose, mean serum concentration, and time) as well as to other psychotropic drugs (anticonvulsants, antidepressants, antipsychotics). Associations of potential risk factors were tested by comparing subjects meeting the criterion of at least one low value of eGFR (<60 units) or not, in bivariate comparisons using ANOVA methods (t-scores) for continuous measures and contingency tables (χ 2) for categorical measures, followed by multivariable logistic regression modeling. In order to differentiate effects on eGFR of age and lithium exposure, we also sampled subjects matched for long-term lithium exposure (20–25 years), but starting treatment at ages <40 vs. ≥40 years. Data are shown as mean ± standard deviation (SD) or with 95% confidence interval (CI), unless stated otherwise. Analyses employed commercial software: Statview.5 (SAS Institute, Cary, NC, USA; for spreadsheets), and Stata.12 (StataCorp, College Station, TX, USA).


Subject characteristics

The pooled study sample consisted of 312 adult, bipolar disorder subjects, treated with lithium carbonate for 8–48 (mean 17.9 ± 8.62) years (with or without other treatments), representing a total exposure of 6142 person-years. Selected characteristics of subjects from each site (subject count, age at entry to study site, age at last contact, and years treated with lithium) are summarized in Table 2. The proportion of women/men was 57.7/42.3%; age at study site intake averaged 37.9 ± 12.9 (range 11–76) years, and last age averaged 55.8 ± 14.2 (range 20–89) years. Diagnoses were 78.2% bipolar I and 21.8% bipolar II, with an average age at illness-onset of 28.5 ± 11.1 years.

Metabolic parameters at baseline and during lithium treatment

Summary data for average measures and their status across years of treatment with lithium are based on 2669 assays (Table 3). They include: lithium carbonate dose (833 ± 311 mg/day), mean daily trough serum concentrations of lithium (0.656 ± 0.184 mEq/L), body-mass index (BMI, 27.0 ± 4.86 kg/m2), serum glucose concentration (97.3 ± 28.4 mg/dL), blood urea nitrogen (BUN, 26.1 ± 12.9 mg/dL), serum creatinine concentration (0.92 ± 0.24 mg/dL), and estimated glomerular filtration rate (eGFR; 83.3 ± 21.8 mL/min/1.73 m2). In addition, white blood cell count ([WBC] not shown) was initially 7.29 and finally 7.59 × 10−3/µL, without appreciable change over years of lithium treatment.
Table 3

Metabolic parameters in lithium-treated bipolar disorder patients

Exposure (years)


Lithium dose (mg/day)

Serum [Li+] (mEq/L)

BMI (kg/m2)

Glucose (mg/dL)

BUN (mg/dL)

Creatinine (mg/dL)

eGFR (mL/min/1.73 m2)



797 ± 283

0.594 ± 0.201

25.9 ± 4.81

88.1 ± 14.3

23.7 ± 11.4

0.87 ± 0.19

94.2 ± 23.3



859 ± 282

0.638 ± 0.171

27.9 ± 5.87a

90.5 ± 16.3

22.1 ± 10.4

0.86 ± 0.17

94.8 ± 22.2



877 ± 296a

0.658 ± 0.185

27.3 ± 5.10a

90.9 ± 17.9

23.8 ± 10.8

0.87 ± 0.17

91.2 ± 21.1



875 ± 310a

0.656 ± 0.177

27.5 ± 5.15a

97.4 ± 28.6a

24.5 ± 11.2

0.90 ± 0.19

86.1 ± 20.1a



858 ± 320

0.672 ± 0.188

27.0 ± 4.57

95.3 ± 24.0a

25.4 ± 11.7

0.91 ± 0.21

83.9 ± 20.2a



815 ± 305

0.671 ± 0.191

27.6 ± 4.71a

98.6 ± 28.4a

26.9 ± 14.1

0.93 ± 0.24a

78.8 ± 19.3a



716 ± 289a

0.651 ± 0.172

27.6 ± 4.30a

103.8 ± 33.5a

31.2 ± 15.7a

0.98 ± 0.29a

72.7 ± 20.1a



647 ± 334a

0.607 ± 0.168

26.6 ± 5.03

121.9 ± 54.9a

33.1 ± 15.8a

1.17 ± 0.48a

62.2 ± 22.9a

Means [95% CI]

312 subjects

833 ± 311 [824–842]

0.656 ± 0.184 [0.650–0.662]

27.0 ± 4.86 [26.5–27.5]

97.3 ± 28.4 [94.1–100.5]

26.1 ± 12.9 [24.7–27.5]

0.92 ± 0.24 [0.89–0.95]

83.3 ± 21.8 [80.9–85.7]

Change (%/year)

2669 assays

–0.777 [–0.654 to –0.901]

–0.005 [–0.118 to –0.118]

+0.162 [0.011–0.311]

+0.787 [0.619–0.954]

+1.41 [1.10–1.72]

+0.724 [0.609–0.839]

–0.915 [–0.822 to –1.01]

p value [t-score]

2669 assays

<0.0001 [12.4]

0.94 [0.077]

0.04 [2.11]

<0.0001 [9.21]

<0.0001 [8.91]

<0.0001 [12.4]

<0.0001 [19.1]

Data are based on means of N measurements (of a total of 2669) for 312 subjects over stated exposures to lithium treatment

Not shown are data for white blood cell counts (WBC), which did not change appreciably (initital: 7.29, final: 7.59 × 10–3 per µL)

BMI (body-mass index [kg/m2]), BUN (blood urea nitrogen [mg/dL]), creatinine [mg/dL], eGFR (estimated glomerular filtration rate for creatinine [mL/min/1.73 m2]), glucose (not necessarily fasting [mg/dL]), WBC (white blood cell count [thousands/µL])

aValues differ significantly from baseline measure, based on Tukey–Kramer post hoc tests comparing each exposure-interval to baseline values

The dose of lithium carbonate declined significantly over the years (0.78%/year) whereas serum lithium concentrations remained stable over time, reflecting dosing adjustments as lithium clearance decreased with advancing age (Table 3). BMI increased slightly, from 25.9 initially to a final mean value of 26.6 kg/m2, at a rate of 0.16%/year, and did not differ significantly between those given psychotropic drugs other than lithium or not (27.0 ± 5.36 vs. 26.3 ± 3.72 kg/m2; t = 1.36, p = 0.18). Serum glucose concentration also rose significantly over years of treatment and with advancing age, at 0.79%/year. BUN increased appreciably (from 23.7 to 33.1 mg/dL), at a rate of 1.4%/year, and creatinine rose at about half the rate of BUN, from 0.87 to 1.17 mg/dL, at 0.72%/year.

The metabolic measure of particular interest, eGFR, declined from a mean at intake of 94.2, to a final average of 62.2 mL/min/1.73 m2, at an average rate of decline of 0.915%/year (Table 3). Times to first-observed significant increases in various measures vs. baseline included: BMI, just after the first year; glucose, from years 6–10; creatinine, years 16–20; and BUN, years 21–30. Decline of eGFR was noted starting from years 6–10, with a projected decline to the lower limit of normal (60 units) after 30 or more years of exposure to lithium (Table 3).

Staging of renal deficiency

We considered changes in the prevalence of stages of renal function based on standard values (American National Kidney Foundation, NKF 2002, 2014) of eGFR, vs. years of lithium treatment (Fig. 1). The prevalence of normal or Stage I eGFR (≥90 mL/min/1.73 m2) declined over years of lithium exposure (and advancing age), from 48.3% at intake to 9.80% after 31–48 years of exposure, whereas Stage 2 (60–89 units) declined slightly (from 50.8 to 44.1% of subjects), and the prevalence of abnormal eGFR Stages 3 and 4 eGFR (15–59 units) increased from 0.85 to 46.1%. No subject reached end-stage renal failure (Stage 5). The relative risk of each stage by sex (women/men) was: Stage 1, 0.72 (more in men); Stage 2, 1.11; Stage 3, 1.68; and Stage 4, 9.29 (all three more in women); these sex-differences were highly significant (overall χ 2 [df = 3] = 51.3, p < 0.0001).
Fig. 1
Fig. 1

Proportion (%) of subjects with Stages 1, 2, or 3 and 4 of renal function vs. years of lithium exposure. By linear regression, the prevalence of Stage 1 renal function (normal) declined highly significantly (slope [β]: −1.12 [CI −1.36 to −0.88]; t = 10.6, p < 0.0001); Stage 2 (mild dysfunction) remained stable (β: –0.035 [CI −0.373 to 0.303], t = 0.23, p = 0.82); and Stages 3 + 4 increased highly significantly (β: +1.15 [CI 0.91–1.40], t = 10.7, p < 0.0001)

Comparison of subjects with low vs. normal eGFR

A total of 92 (29.5%) of the 312 subjects had at least one estimate of eGFR below the lower limit of normal (<60 mL/min/1.73 m2). Based on the widely accepted criterion of ≥2 low values (Azab et al. 2015), the risk of eGFR < 60 units was 18.1% [CI 13.9–22.7]. Characteristics of subjects with vs. without low eGFR values were compared in initial bivariate comparisons (Tables 4, 5). Subjects with significantly lower eGFR were (a) more often women than men; (b) older at illness-onset, at starting lithium, and at final observation; (c) significantly less likely to be given co-treatments with anticonvulsants or antipsychotics; and (d) having significantly lower initial values of eGFR (Table 4). In addition, measures associated with low eGFR based on all assays, included (e) older at the time of assays; (f) more likely to have medical comorbidities (mainly cardiovascular diseases, diabetes, hypercholesterolemia, hypertension, hypertriglyceridemia, hypothyroidism, or respiratory diseases); (g) longer exposure to lithium; (h) lower average doses of lithium carbonate; (i) without differences in mean serum lithium concentrations; (j) higher mean BUN; (k) higher serum glucose concentration; and (l) higher BMI (Table 5). Factors not associated with low eGFR included (a) diagnosis; (b) educational level; (c) metabolic syndrome; (d) abuse of alcohol or drugs; (e) cigarette smoking; (f) lifetime suicidal behavior, and (g) serum TSH levels.
Table 4

Factors associated with vs. without low eGFR among 312 bipolar disorder subjects treated long-term with lithium


Low eGFRa

Normal eGFR

p-value [χ 2 or t-score]




Sex (%)


0.003 [8.98]









Ages (years)

 Illness onset

31.8 [29.4–34.2]

27.1 [25.7–28.5]

0.0007 [3.41]

 Started lithium

42.5 [39.8–45.2]

35.9 [34.2–37.6]

<0.0001 [4.19]

 Final lithium

65.0 [62.4–67.6]

52.0 [50.3–53.7]

<0.0001 [8.09]

Co-treatments (%)




0.001 [10.4]




0.01 [6.40]




0.07 [3.25]

Initial eGFR

77.2 ± 16.1

94.6 ± 21.9

<0.0001 [6.74]

Means are with 95% CI. Serum lithium concentration is in mEq/L; dose is of lithium carbonate is total mg/day. Additional factors not associated with low eGFR: (1) diagnosis (bipolar I vs. bipolar II), (2) education, (3) metabolic syndrome (overall risk = 30.4%), (4) any substance abuse, (5) alcohol abuse, (6) smoking, (7) any suicidal act, (8) serum TSH. Medical illnesses include cardiovascular and metabolic syndromes

aLow eGFR: subjects with at least one value <60 mL/min/1.73 m2; the observed rate of such subjects was 92/312 (29.5%), but 312/2669 assays (11.3%)

Table 5

Measures associated with vs. without low eGFR among 2669 assays in 312 bipolar disorder subjects treated long-term with lithium


Low eGFRa

Normal eGFR

p-value [χ 2 or t-score]

Age at assay

62.7 [61.4–64.0]

48.0 [47.5–48.5]

<0.0001 [18.3]

Medical comorbidity (%)b



<0.0001 [41.3]

Lithium exposure

 Years treated

19.6 [18.5–20.7]

11.2 [10.9–11.5]

<0.0001 [16.3]

 Mean dose

588 [554–622]

884 [871–896]

<0.0001 [15.5]

 Mean serum [Li+]

0.65 [0.63–0.68]

0.66 [0.65–0.67]

0.32 [0.99]

Physiological measures


36.7 [34.3–39.1]

24.6 [24.0–25.2]

<0.0001 [12.6]


108 [103–112]

95.8 [94.4–97.2]

<0.0001 [5.88]


28.5 [26.2–30.8]

26.4 [25.9–26.9]

0.03 [2.22]

Means are with 95% CI. Serum lithium concentration is in mEq/L; dose is of lithium carbonate is total mg/day. Additional factors not associated with low eGFR: (1) diagnosis (bipolar I vs. bipolar II), (2) education, (3) metabolic syndrome (overall risk = 30.4%), (4) any substance abuse, (5) alcohol abuse, (6) smoking, (7) any suicidal act, (8) serum TSH. Medical illnesses include cardiovascular and metabolic syndromes

aLow eGFR: subjects with at least one value <60 mL/min/1.73 m2; the observed rate of such subjects was 92/312 (29.5%), but 312/2669 assays (11.3%)

bMost frequent medical comorbidities are: cardiovascular diseases, diabetes, hypercholesterolemia, hypertension, hypertriglyceridemia, hypothyroidism, and respiratory diseases

Of note, antipsychotic drugs (59.2% of all subjects) were given with lithium more than either anticonvulsants (38.6%) or antidepressants (33.1%). Based on multiple variable logistic regression modeling, adjusted for age and sex (not shown), mood-altering anticonvulsants were associated with shorter exposure to lithium and lower serum concentrations. Use of antipsychotics was significantly greater among subjects diagnosed with bipolar I than II disorder, as well as shorter exposure to lithium but at higher doses and serum concentrations. Antidepressants were given more often to bipolar II than bipolar I disorder subjects.

Declining eGFR with age and exposure to lithium

As expected, advancing age and years of lithium treatment were associated with low values for eGFR (<60 mL/min/1.73 m2), with corresponding increases in rates of elevated serum creatinine concentration (defined as >1.2 mg/dL, based on the lower standard value for women rather than that of 1.5 mg/dL for men) (Fig. 2; Table 3). The rate of decline (slope function as %/year) averaged 0.710%/year of age, with a nonsignificantly steeper decline among women than men (0.756 vs. 0.631%/year), and 0.915%/year of lithium exposure, with a significantly greater (non-overlapping CIs) rate of decline among women than men (0.934 vs. 0.785%/year of lithium; Table 6). The overall observed rate of decline of eGFR was 28.9% greater for years of lithium treatment than for years of age (0.915 vs. 0.710%/year; Table 6).
Fig. 2
Fig. 2

Values of eGFR (mL/min) [with 95% CI] among men and women: a vs. age; b vs. years of lithium treatment, pooled from 12 international sites, involving 2669 measurements among 312 bipolar disorder subjects treated with lithium for 8–44 years

Table 6

Rate of decrease of eGFR with age and lithium exposure (%/year)


eGFR decrease, %/year [95% CI] (n)

Age: healthy adults

Age: lithium-treated

Years of lithium

All subjects

0.637 [0.497–0.777] (365)

0.710 [0.653–0.767] (312)

0.915 [0.822–1.08] (312)


0.488 [0.361–0.616] (160)

0.631 [0.545–0.717] (132)

0.785 [0.546–0.717] (132)


0.754 [0.580–0.928] (205)

0.756 [0.682–0.829] (180)

0.934 [0.815–1.05] (180)

Lithium-treated subjects are from the present study. Data for healthy adults are adapted from Rule et al. (2004) for clearance of iothalamate. Rates of GFR decrease as %/year are computed as [initial eGFR − observed eGFR]/[initial eGFR] × 100 with 95% confidence intervals and number (n) of subjects (eGFR is in units of mL/min/1.73 m2)

For comparison with subjects not exposed to lithium, we obtained data from a study by Rule et al. (2004) who measured the effect of age in 365 healthy subjects on eGFR estimated as in the present study. These data indicate a nonsignificantly lower rate of decline with age without than with lithium treatment (0.637 vs. 0.710%/year), as well as a slightly larger decreases among women than men (Table 6). In addition, the rate of decline of eGFR was significantly greater with years of exposure to lithium (0.915%/year) than with age in subjects not exposed to lithium (0.637%/year; Table 6).

Renal effects of age at starting lithium treatment

Given the uncertain relative contributions of aging and exposure to lithium on declining eGFR, we considered a restricted sample of 610 assays, matched for long-term treatment with lithium for 20–25 years (mean for both = 22 years), but starting treatment at ages <40 vs. ≥40 years (Table 7). Mean eGFR was highly significantly lower among participants starting lithium at age ≥ 40 years. Moreover, risk of low values of eGFR was nearly twice as high (1.94-times) among the older subjects, despite similar exposure to lithium.
Table 7

Patients started on lithium treatment below or above age 40


Age < 40

Age ≥ 40

p-value (t or χ 2)

Subjects (n)



Years of lithium

22.3 ± 1.69

22.1 ± 1.63

0.123 (0.35)

Mean eGFR

77.6 ± 19.9

68.3 ± 17.9

<0.0001 (4.02)

eGFR < 60 units (%)



<0.0001 (63.8)

Multivariable regression modeling

Finally, we carried out multivariable logistic regression modeling of factors associated with low eGFR (<60 mL/min/1.73 m2). Factors remaining independently and significantly associated ranked: (a) longer treatment with lithium, (b) lower mean daily dose of lithium carbonate, (c) higher mean serum lithium concentration, (d) older age at the time of assays, (e) co-occurring medical illness (Table 8). Not significantly associated with low eGFR in such modeling were sex, BMI, and co-treatment with an anticonvulsant, antipsychotic, or antidepressant drugs. Of note, serum concentration was associated with low eGFR only when adjusted for age, dose, and duration of exposure (Table 8), but not without such adjustment (Tables 4, 5).
Table 8

Multivariate logistic regression model for factors associated with low eGFR (<60 mL/min/1.73 m2)


Odds ratio [95% CI]



Longer lithium treatment (years)

1.07 [1.04–1.09]



Lower mean lithium dose (mg/day)

1.003 [1.002–1.004]



Higher mean serum [Li+]

4.47 [4.36–43.5]



Older age at assay

1.04 [1.02–1.06]



Co-occurring medical illness

2.11 [1.28–3.49]




Among 312 adult bipolar disorder patients, treated for 8–48 years with lithium carbonate (6142 person-years of exposure), from 12 international collaborating centers we found an incidence of low eGFR (<60 units) of 18.1% of subjects for ≥2 low values. The risk was 29.5% using a broad criterion of one low value, for which the overall female/male risk ratio was 1.76. Stage 1 eGFR (values of ≥90 units) was 39% more prevalent among men than women, whereas Stages 2 (60–89; by 11%), 3 (30–59; 68%), and 4 (15–29 units, by 9.3-fold) were more frequent among women. No subject reached end-stage renal dysfunction (ESRD), perhaps reflecting the source of study data from specialized mood-disorder clinics where close clinical follow-up would lead to suspension of treatment before reaching ESRD. Close clinical monitoring probably is also reflected in the lack of decline in average serum concentrations of lithium over years of treatment, despite a significant decline in total daily dose, presumably adjusted to maintain stable blood levels.

A particularly important finding is that eGFR declined with longer exposure to lithium treatment, but also with corresponding increases in age (Fig. 2; Table 6). Both factors were sustained as significant and independent in multivariable modeling (Table 8). Effects of aging on renal function are well established even among human subjects without known disease or toxic factors (Rule et al. 2004; Weinstein and Anderson 2010). Although we did not have a comparison sample of patients followed over time without lithium treatment, we could compare rates of decline of eGFR as a function of age and of time of exposure to lithium, and with reported rates of decline in healthy subjects (Rule et al. 2004). Without lithium treatment, the rate of decline in eGFR (%/year) vs. age in normal subjects averaged 0.637 [CI 0.497–0.777] (Rule et al. 2004), compared to 0.710 [0.653–0.767] for age in lithium-treated subjects, and to 0.915 [0.822–1.08] for years of lithium treatment (Table 6). These estimates are similar, with overlapping confidence intervals for the effect of aging, but a higher rate with lithium exposure. Additional reported data indicate a rate of decline of eGFR in healthy subjects of 0.708 [0.644–0.772]  %/year (American National Kidney Foundation, NKF 2014)—a value even closer to that found in our study for age among lithium-treated subjects. We also addressed the relative contributions to declining eGFR by considering a sample of subjects matched for long-term exposure to lithium (22 years), but starting the treatment at ages <40 vs. ≥40 years (Table 7). Mean eGFR was significantly higher among participants who started lithium at older ages, and the risk of low values of eGFR was nearly twice greater among the older subjects, despite similar exposure to lithium. These findings indicate that effects of aging were greater than the exposure to lithium. Moreover, adverse effects of lithium on renal function may be greater at older ages.

The rate of decline of eGFR averaged 0.92% per year of lithium treatment, and was 19% higher among women than men. The observed overall rate of decline is consistent with most (Bendz et al. 1996, 2010; Bocchetta et al. 2013, 2015; Close et al. 2014; Aiff et al. 2015; Shine et al. 2015; Kessing et al. 2015; Hayes et al. 2016), but not all (Clos et al. 2015) retrospective reports on the effects of lithium on kidney function. In the study by Clos et al. (2015), however, patients were exposed to lithium for an average of 55 months, possibly too brief to support detection of effects on kidney function (Davis et al. 2015; Bocchetta et al. 2016). Interestingly, however, a similar lack of effect of lithium on renal function was found in a 4-years prospective study in elderly patients with mild cognitive impairment (Aprahamian et al. 2014). In the present findings, average values of eGFR became significantly lower than baseline levels by 6–10 years of treatment, and a mean decline to the lower limit of normal (60 units) required ≥30 years of exposure to lithium (Table 3). Other reports of long-term lithium treatment effects on renal function are consistent with this observation (Bendz et al. 2010; Bocchetta et al. 2015; Shine et al. 2015). We also found that risk of later low values of eGFR were strongly predicted by lower initial values (Table 4). Exposure to lithium treatment needed to be at least 6–10 years to be associated with significant decreases of eGFR (Table 3).

Our finding of greater risk of a decline in eGFR among women is also consistent with some recent reports (Bocchetta et al. 2015; Shine et al. 2015) suggesting a higher vulnerability of women to developing lithium-related effects on kidney. Of note, however, other studies have found greater risk of declining eGFR among men (Rybakowski et al. 2012; Bocchetta et al. 2013) or no sex difference (Aiff et al. 2015).

Serum concentrations of urea (BUN) increased by 1.41%/year, glucose by 0.787%/year, and creatinine by 0.724%/year—all rising with longer exposure to lithium and correspondingly advancing age. The observed increase in serum glucose levels contrasts with a study reporting a nonsignificant increase in glucose levels after four years of treatment with lithium in elderly patients (Aprahamian et al. 2014). Interestingly, studies in animals evaluating the effects of lithium on glucose metabolism also may be discordant with our findings (Shah and Pishdad 1980; Tabata et al. 1994). Indeed, whereas Shah and Pishdad (1980) found that lithium induced the hyperglycemia in rats, Tabata et al. (1994) found a markedly increased sensitivity of glucose transport to insulin after lithium treatment.

We also found that average BMI increased by 0.162%/year of treatment with lithium, with a significant increase over baseline values by the end of the first year of exposure, but little more thereafter (Table 3). This finding confirms that lithium may contribute to weight gain (Mathew et al. 1989; Atmaca et al. 2002), although the effect might reflect exposure to other weight-increasing agents including antipsychotic drugs (Calkin et al. 2009). However, the potential adverse risks associated with long-term treatment with lithium need to be balanced against major clinical benefits of treatment with lithium (McKnight et al. 2012; Severus and Bauer 2013; Kessing et al. 2015).

Several factors were associated with loss of eGFR during long-term treatment with lithium (Tables 4, 5, 6, 7 and 8). Notably, declining eGFR was associated with serum lithium concentrations only when adjusted for age, dose of lithium, and duration of lithium exposure, whereas total daily doses of lithium carbonate were actually lower with low eGFR, in association with older age (Tables 4, 5, and 8). These findings suggest that dose was adjusted to maintain therapeutic serum levels in the face of declining renal clearance of lithium and with age. We also found that medical comorbidities (especially diabetes and hypertension) were associated with declining eGFR. In contrast, use of adjunctive treatments, especially modern antipsychotic drugs and mood-altering anticonvulsants, were associated with less risk of low eGFR values (Tables 4, 5). These associations are not readily explained. Patients with low eGFR were older, had more general medical comorbidity, and were given fewer psychotropic drugs of all kinds as well as lower doses of lithium. Of note, there is suggestive evidence that anticonvulsants and antipsychotics may themselves contribute to risk of renal damage (Hwang et al. 2014; Kessing et al. 2015). Other findings implicate episodes of acute lithium intoxication (possibly an indication of more aggressive treatment) with declining renal function (Rej et al. 2012).

There may be effects of once-daily vs. multiple daily dosing with lithium on renal function (Carter et al. 2013; Castro et al. 2016). Some evidence suggests less renal toxicity with once-daily dosing, but the findings are inconsistent, and may be confounded by likely use of lower doses with once-daily regimens (Schou et al. 1982; Carter et al. 2013). Moreover, the observed effects pertain mainly to small reductions in 24-h urine volume (Kusalic and Engelsmann 1996). Once-daily dosing is perhaps best reserved for young, vigorous patients given moderate doses of lithium to limit the potentially toxic impact of high, daily peak serum concentrations. Reducing lithium dose might be expected to limit toxic effects as was supported by present findings (Tables 4, 5, assuming that dose was not lowered because of declining renal function). Lithium dose can be reduced by use of combinations with other agents with mood-stabilizing effects, including some anticonvulsants or antipsychotics.

Consideration of these factors during appropriately close, long-term clinical monitoring should help to limit risks of renal impairment with long-term lithium treatment (Paul et al. 2010). In addition, there may be benefits in monitoring serum concentrations of lithium levels relatively frequently, especially in elderly patients. It has been suggested that lithium levels should be monitored every 3 months since even a single occurrence of a level higher than 1.0 mEq/L may result in a modest but significant decrease of the GFR lasting for at least 3 months (Bauer et al. 2006; Van Beneden et al. 2011; Kirkham et al. 2014; Davis et al. 2015; Shine et al. 2015). In general, we would emphasize the importance of appropriate selection of patients for long-term lithium treatment, maintaining them on minimum effective doses and daily trough serum concentrations especially for older populations, and regular monitoring to assess adherence to prescribed treatment. These principles of safe practice are important to emphasize, especially as many mood-disorder patients are followed by primary-care clinicians and are not followed in specialized programs directed by experts (Müller-Oerlinghausen et al. 2012).


The present findings should be interpreted in the context of some limitations. First, the study is retrospective in nature. However, clinical data were collected longitudinally in specialized mood-disorder clinics where patients are followed up systematically and at regular intervals, increasing the statistical accuracy of gathered information. Second, the main measure of renal function in this study was estimated GFR based on serum concentrations of creatinine, and not on independently verified clearance of an exogenous test molecule. The formulas employed may not adequately reflect the rate of glomerular filtration at very high concentrations of creatinine, such as >1.75 mg/dL (Levey et al. 2009; Stevens 2013). Nevertheless, eGFR is widely employed measure of renal function and is readily obtained for routine clinical use. Finally, we lacked a comparison group without lithium treatment, leaving the important question of effects of aging vs. of lithium on eGFR unresolved.


This multisite, international, long-term study found significant changes in renal function and other metabolic measures in association with very prolonged treatment with lithium carbonate given to prevent recurrences of bipolar disorder. It adds to evidence that long-term lithium treatment is associated with a decline in renal function as expressed by significant decreases of eGFR over time. We found moderate decreases in eGFR after prolonged exposure to lithium (at least 6–10 years) and advancing age, along with increases in serum creatinine and BUN concentrations, and small increases in glucose levels and BMI. No cases of severe or end-stage renal failure were encountered, probably owing to close clinical monitoring and timely interventions in cases with declining renal function. We found greater decreases in eGFR among women than men, and following lower initial values of eGFR, as well as when lithium treatment was started at older ages. The study findings contribute to clarifying relationships between long-term lithium treatment and its metabolic safety profile. Overall, this study and those summarized above (Table 1) indicate, with some notable inconsistencies, that there were major risks of declining eGFR with very prolonged treatment with lithium salts, but that effects of advancing age also are prominent and confound quantification of risk-by-time specific to lithium exposure. Noteworthy risk factors for low eGFR included female sex, higher serum lithium level, longer lithium treatment, lower initial eGFR, and medical comorbidity, as well as older age. A clinically favorable conclusion is that emerging decreases in renal function can be detected readily with regular metabolic monitoring, and probably modified by timely interventions that include an increasing number of apparently effective treatment options to lithium.


Authors’ contributions

All the authors contributed to this paper by providing data and discussing the design and results of the study, and preparation of this report. All the authors read and approved the final manuscript.


The authors offer their thanks to Kathleen Cairns, Julie Garnham, Terry McCarvill, and Claire Slaney for help with data collection. This study was supported by the Aretæus Foundation of Rome and by Angelini Corp. (LT); by Grant 64410 from the Canadian Institutes of Health Research (to MA); by the Spanish Ministry of Economy and Competitiveness (PI12/00912; PN 2008–2011); by the Grant/research support from Deutsche Forschungsgemeinschaft, European Commission (FP7); by the American Foundation for Suicide Prevention, and by the Bundesministerium für Bildung und Forschung (BMBF)(to MB); by a German Excellence Initiative to the Graduate School of Life Sciences, University of Wurzburg, and by the RTG 1256/2 “gk emotions” (to JV); Instituto de Salud Carlos III, Subdirección General de Evaluación y Fomento de la Investigación, Fondo Europeo de Desarrollo Regional, Unión Europea, “Una manera de hacer Europa,” and by CIBERSAM and the Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement (2014-SGR-398 to EV); by a German Ministry of Education and Research Grant (01EE1404C; to AR); (to JKR); and by a grant from the Bruce J. Anderson Foundation and the McLean Private Donors Research Fund (to RJB).

Competing interests

Drs. Abramowicz, Alda, Bocchetta, Bolzani, Calkin, Chillotti, Hidalgo-Mazzei, Manchia, Müller-Oerlinghausen, Murru, Pinna, Quaranta, Reginaldi, Reiff, Saiger, Selle, Vázquez, Veeh, and members of the immediate families of all authors have no potential conflicts of interest to disclose, and their consulting relationships to industry are reported above. Dr. Baldessarini is a consultant to Britannia Pharmaceuticals, Ltd. and participates in continuing medical education programs sponsored by Harvard Medical School, McLean Hospital, and the New England Educational Institute. Dr. Bauer has been a consultant for Ferrer Internacional, Janssen, Lilly, Lundbeck, Neuraxpharm, Otsuka, and Servier Corporations, and has received speaker honoraria from AstraZeneca, Lilly, Lundbeck, Otsuka and Pfizer Corporations. Dr. Rybakowski is a consultant to Janssen-Cilag, Lundbeck, and Servier Corporations. Dr. Stamm has received speaker honoraria from Lundbeck and BristolMyers Squibb and is a consultant to Servier Corporation. Dr. Tondo is consultant for Angelini Corporation. Dr. Vieta has received grants and served as consultant, advisor, or CME speaker for the following entities: AB-Biotics, Actavis, Allergan, AstraZeneca, Bristol-Myers Squibb, Dainippon Sumitomo Pharma, Ferrer, Forest Research Institute, Gedeon Richter, Glaxo-SmithKline, Janssen, Lundbeck, Otsuka, Pfizer, Roche, Sanofi-Aventis, Servier, Shire, Sunovion, Takeda, and Telefónica Corporations, the Brain and Behavior Foundation, the Spanish Ministry of Science and Innovation (CIBERSAM), the Seventh European Framework Programme (ENBREC), and the Stanley Medical Research Institute.

Availability of data and materials

Data were made available by all participants/authors of the study.

Consent for publication

All patients signed an informed consent to publication of anonymous and aggregate data derived from their medical records.

Ethics approval and consent to participate

The study has been approved by local Ethical Committee according to national laws which allow the anonymous and aggregate use of human data if not involved in any experimental designs.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors’ Affiliations

Department of Psychiatry, Harvard Medical School, Boston, MA, USA
The International Consortium for Mood & Psychotic Disorders Research, MRC 306, McLean Hospital, 115 Mill Street, Belmont, MA 02478-9106, USA
Lucio Bini Mood Disorders Centers, Cagliari and Rome, Italy
Department of Adult Psychiatry, Poznan University of Medical Sciences, Poznan, Poland
Department of Psychiatry, Dalhousie University, Halifax, NS, Canada
Department of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy
Unit of Clinical Pharmacology, Azienda Ospedaliero-Universitaria, Cagliari, Italy
Viarnetto Psychiatric Clinic, Lugano, Switzerland
Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain
Section of Psychiatry, Department of Medical Science and Public Health, University of Cagliari, Cagliari, Italy
Department of Pharmacology, Dalhousie University, Halifax, NS, Canada
Freie Universität Berlin, Charité Universitäts-Medizin, Berlin, Germany
Department of Experimental and Clinic Medicine, Section of Psychiatry, University of Pisa & Institute of Behavioral Science, Pisa, Italy
Department of General Psychology, Clinical Psychology, University of Padua, Padua, Italy
Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt, Frankfurt-am-Main, Germany
Department of Psychiatry, Charité Universitäs-Medizin, Berlin, Germany
Brandenburg Medical School, Neureppin, Germany
NeSMOS Department, ‘Sapienza’ University and Lucio Bini Mood Disorders Center, Rome, Italy
Department of Psychiatry, Queens University, Kingston, Ontario, Canada
Department of Neuroscience, Palermo University, Buenos Aires, Argentina


  1. Aiff H, Attman PO, Aurell M, Bendz H, Schön S, Svedlund J. End-stage renal disease associated with prophylactic lithium treatment. Eur Neuropsychopharmacol. 2014;24:540–4.View ArticlePubMedGoogle Scholar
  2. Aiff H, Attman PO, Aurell M, Bendz H, Ramsauer B, Schön S, Svedlund J. Effects of 10 to 30 years of lithium treatment on kidney function. J Psychopharmacol. 2015;29:608–14.View ArticlePubMedGoogle Scholar
  3. Albrecht J, Kampf D, Müller-Oerlinghausen B. Renal function and biopsy in patients on lithium therapy. Pharmacopsychiatry Neuropsychopharmacol. 1980;13:228–34.Google Scholar
  4. Alsady M, Baumgarten R, Deen PM, de Groot T. Lithium in the kidney: friend and foe? J Am Soc Nephrol. 2016;27:1587–95.View ArticlePubMedGoogle Scholar
  5. American National Kidney Foundation. Clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis. 2002;39:S1–266.Google Scholar
  6. American National Kidney Foundation, NKF. Frequently asked questions about GFR estimates; 2014. Accessed 10 Sept 2016.
  7. Aprahamian I, Santos FS, dos Santos B, Talib L, Diniz BS, Radanovic M, et al. Long-term, low-dose lithium treatment does not impair renal function in the elderly: 2-year randomized, placebo-controlled trial followed by single-blind extension. J Clin Psychiatry. 2014;75:e672–8.View ArticlePubMedGoogle Scholar
  8. Atmaca M, Kuloglu M, Tezcan E, Ustundag B. Weight gain and serum leptin levels in patients on lithium treatment. Neuropsychobiology. 2002;46:67–9.View ArticlePubMedGoogle Scholar
  9. Azab AN, Shnaider A, Osher Y, Wang D, Bersudsky Y, Belmaker RH. Lithium nephrotoxicity. Int J Bipolar Disord. 2015;3:13.View ArticlePubMed CentralGoogle Scholar
  10. Baldessarini RJ. Chemotherapy in Psychiatry. 2nd ed. New York: Springer Press; 2013.View ArticleGoogle Scholar
  11. Baldessarini RJ, Tondo L. Are renal tumors associated with lithium treatment? Int J Bipolar Disord. 2014;2:6.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Bauer M, Gitlin M. The essential guide to lithium treatment. Cham: Springer Press; 2016.View ArticleGoogle Scholar
  13. Bauer M, Grof P, Müller-Oerlinghausen B, editors. Lithium in neuropsychiatry: the comprehensive guide. Abingdon: Informa Press; 2006.Google Scholar
  14. Bendz H. Kidney function in a selected lithium population. A prospective, controlled, lithium-withdrawal study. Acta Psychiatr Scand. 1985;72:451–63.View ArticlePubMedGoogle Scholar
  15. Bendz H, Schön S, Attman PO, Aurell M. Renal failure occurs in chronic lithium treatment but is uncommon. Kidney Int. 2010;77:219–24.View ArticlePubMedGoogle Scholar
  16. Bendz H, Sjödin I, Aurell A. Renal function on and off lithium in patients treated with lithium for 15 years or more. A controlled, prospective lithium-withdrawal study. Nephrol Dial Transpl. 1996;11:457–60.View ArticleGoogle Scholar
  17. Bocchetta A, Ardau R, Carta P, Ligas F, Sardu C, Pani A, Del Zompo M. Duration of lithium treatment is a risk factor for reduced glomerular function: a cross-sectional study. BMC Med. 2013;11:33.View ArticlePubMedPubMed CentralGoogle Scholar
  18. Bocchetta A, Ardau R, Fanni T, Sardu C, Piras D, Pani A, Del Zompo M. Renal function during long-term lithium treatment: a cross-sectional and longitudinal study. BMC Med. 2015;13:12.View ArticlePubMedPubMed CentralGoogle Scholar
  19. Bocchetta A, Sardu C, Piras D, Pani A (2016) Long-term lithium and estimated glomerular filtration rate. Lancet Psychiatry 3(2):105-106View ArticlePubMedGoogle Scholar
  20. Calkin C, van de Velde C, Růzicková M, Slaney C, Garnham J, Hajek T, et al. Can body mass index help predict outcome in patients with bipolar disorder? Bipolar Disord. 2009;11:650–6.View ArticlePubMedPubMed CentralGoogle Scholar
  21. Carter L, Zolezzi M, Lewxzyk A. An updated review of the optimal lithium dosage regimen for renal protection. Can J Psychiatry. 2013;58:595–600.View ArticlePubMedGoogle Scholar
  22. Castro VM, Roberson AM, McCoy TH, Wiste A, Cagan A, Smoller JW, et al. Stratifying risk for renal insufficiency among lithium-treated patients: electronic health record study. Neuropsychopharmacology. 2016;41:1138–43.View ArticlePubMedGoogle Scholar
  23. Clos S, Rauchhaus P, Severn A, Cochrane L, Donnan PT. Long-term effect of lithium maintenance therapy on estimated glomerular filtration rate in patients with affective disorders: a population-based cohort study. Lancet Psychiatry. 2015;2:1075–83.View ArticlePubMedGoogle Scholar
  24. Close H, Reilly J, Mason JM, Kripalani M, Wilson D, Main J, Hungin AP. Renal failure in lithium-treated bipolar disorder: a retrospective cohort study. PLoS ONE. 2014;9:e90169.View ArticlePubMedPubMed CentralGoogle Scholar
  25. Coşkunol H, Vahip S, Mees ED, Başçi A, Bayindir O, Tuğlulaŕ I. Renal side-effects of long-term lithium treatment. J Affect Disord. 1997;43:5–10.View ArticlePubMedGoogle Scholar
  26. Davis JM, Rosenbaum A, Shahinian V, Brosius FC. Prevention of lithium-associated renal failure: recent evidence. Lancet Psychiatry. 2015;2:1045–7.View ArticlePubMedGoogle Scholar
  27. Depaulo JR Jr, Correa EI, Sapir DG. Renal glomerular function and long-term lithium therapy. Am J Psychiatry. 1981;138:324–7.View ArticlePubMedGoogle Scholar
  28. Farshchian N, Farnia V, Aghaiani MR, Abdoli N. MRI findings and renal function in patients on lithium therapy. Curr Drug Saf. 2013;8:257–60.View ArticlePubMedGoogle Scholar
  29. Hayes JF, Marston L, Walters K, Geddes JR, King M, Osborn DP. Adverse renal, endocrine, hepatic, and metabolic events during maintenance mood stabilizer treatment for bipolar disorder: a population-based cohort study. PLoS Med. 2016;13:e100205.View ArticleGoogle Scholar
  30. Hullin RP, Coley VP, Birch NJ, Thomas TH, Morgan DB. Renal function after long-term treatment with lithium. Br Med J. 1979;1:1457–79.View ArticlePubMedPubMed CentralGoogle Scholar
  31. Hwang YJ, Dixon SN, Reiss JP, Wald R, Parikh CR, Gandhi S, et al. Atypical antipsychotic drugs and the risk for acute kidney injury and other adverse outcomes in older adults: a population-based cohort study. Ann Intern Med. 2014;161:242–8.View ArticlePubMedGoogle Scholar
  32. Jończyk-Potoczna K, Abramowicz M, Chłopocka-Woźniak M, Strzelczuk-Judka L, Michalak M, Czekalski S, Rybakowski JK. Renal sonography in bipolar patients on long-term lithium treatment. J Clin Ultrasound. 2016;44:354–9.View ArticlePubMedGoogle Scholar
  33. Karaosmanoglu AD, Butros SR, Arellano R (2013) Imaging findings of renal toxicity in patients on chronic lithium therapy. Diagn Interv Radiol 19(4):299–303PubMedGoogle Scholar
  34. Kessing LV, Gerds TA, Feldt-Rasmussen B, Andersen PK, Licht RW. Use of lithium and anticonvulsants and the rate of chronic kidney disease: a nationwide population-based study. JAMA Psychiatry. 2015;72:1182–91.View ArticlePubMedGoogle Scholar
  35. Kirkham E, Skinner J, Anderson T, Bazire S, Twigg MJ, Desborough JA. One lithium level >1.0 mmol/L causes an acute decline in eGFR: findings from a retrospective analysis of a monitoring database. BMJ Open. 2014;4:020.View ArticleGoogle Scholar
  36. Kusalic M, Engelsmann F. Renal reactions to changes of lithium dosage. Neuropsychobiology. 1996;34:113–6.View ArticlePubMedGoogle Scholar
  37. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF III, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.View ArticlePubMedPubMed CentralGoogle Scholar
  38. Licht RW, Grabenhenrich LB, Nielsen RE, Berghöfer A, International Group for the Study of Lithium (IGSLi), et al. Kidney Int. 2014;86:857.View ArticlePubMedPubMed CentralGoogle Scholar
  39. Mathew B, Rao JM, Sundari U. Lithium-induced changes in the body mass index. Acta Psychiatr Scand. 1989;80:538–40.View ArticlePubMedGoogle Scholar
  40. McKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR (2012) Lithium toxicity profile: a systematic review and meta-analysis. Lancet 379(9817):721-728View ArticlePubMedGoogle Scholar
  41. Minay J, Paul R, McGarvey D, Savage G, Stevenson M, Fogarty D, et al. Lithium usage and renal function testing in a large UK community population; a case-control study. Gen Hosp Psychiatry. 2013;35:631–5.View ArticlePubMedGoogle Scholar
  42. Müller-Oerlinghausen B, Bauer M, Grof P. Commentary on a recent review of lithium toxicity: what are its implications for clinical practice? BMC Med. 2012;10:132.View ArticlePubMedPubMed CentralGoogle Scholar
  43. Oliveira JL, Silva Júnior GB, Abreu KL, Rocha Nde A, Franco LF, et al. Lithium nephrotoxicity. Rev Assoc Med Bras. 2010;56:600–6.View ArticlePubMedGoogle Scholar
  44. Paul R, Minay J, Cardwell C, Fogarty D, Kelly C. Meta-analysis of effects of lithium usage on serum creatinine levels. J Psychopharmacol. 2010;24:1425–31.View ArticlePubMedGoogle Scholar
  45. Pottegård A, Hallas J, Jensen BL, Madsen K, Friis S. Long-term lithium use and risk of renal and upper urinary tract cancers. J Am Soc Nephrol. 2016;27:249–55.View ArticlePubMedGoogle Scholar
  46. Rej S, Herrmann N, Shulman K. Effects of lithium on renal function in older adults: systematic review. J Geriatr Psychiatry Neurol. 2012;25:51–61.View ArticlePubMedGoogle Scholar
  47. Rej S, Pira S, Marshe V, Do A, Elie D, Looper KJ, et al. Molecular mechanisms in lithium-associated renal disease: a systematic review. Int Urol Nephrol. 2016;48:1843–53.View ArticlePubMedGoogle Scholar
  48. Rule AD, Gussak HM, Pond GR, Bergstralh EJ, Stegall MD, Cosio FG, Larson TS. Measured and estimated GFR in healthy potential kidney donors. Am J Kidney Dis. 2004;43:112–9.View ArticlePubMedGoogle Scholar
  49. Rybakowski JK, Abramowicz M, Drogowska J, Chłopocka-Woźniak M, Michalak M, Czkalski S. Screening for the markers of kidney damage in men and women on long-term lithium treatment. Med Sci Monit. 2012;18:CR656–60.View ArticlePubMedPubMed CentralGoogle Scholar
  50. Schou M, Amdisen A, Thomsen K, Vestergaard P, Hetmar O, Mellerup ET, Plenge P, Rafaelsen OJ. Lithium treatment regimen and renal water handling: the significance of dosage pattern and tablet type examined through comparison of results from two clinics with different treatment regimens. Psychopharmacology. 1982;77:387–90.View ArticlePubMedGoogle Scholar
  51. Severus E, Bauer M. Managing the risk of lithium-induced nephropathy in the long-term treatment of patients with recurrent affective disorders. BMC Med. 2013;11:34.View ArticlePubMedPubMed CentralGoogle Scholar
  52. Severus E, Taylor MJ, Sauer C, Pfennig A, Ritter P, Bauer M, Geddes JR. Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysis. Int J Bipolar Disord. 2014;2:15.View ArticlePubMedPubMed CentralGoogle Scholar
  53. Shah JH, Pishdad G. The effect of lithium on glucose- and tolbutamide-induced insulin release and glucose tolerance in the intact rat. Endocrinology. 1980;107:1300–4.View ArticlePubMedGoogle Scholar
  54. Shine B, McKnight RF, Leaver L, Geddes JR. Long-term effects of lithium on renal, thyroid, and parathyroid function: a retrospective analysis of laboratory data. Lancet. 2015;386:461–8.View ArticlePubMedGoogle Scholar
  55. Slaughter A, Pandey T, Jambhekar K. MRI findings in chronic lithium nephropathy: a case report. J Radiol Case Rep. 2010;4:15–21.PubMedPubMed CentralGoogle Scholar
  56. Stevens PE (2013) Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med 158(11):825-830View ArticlePubMedGoogle Scholar
  57. Tabata I, Schluter J, Gulve EA, Holloszy JO. Lithium increases susceptibility of muscle glucose transport to stimulation by various agents. Diabetes. 1994;43:903–7.View ArticlePubMedGoogle Scholar
  58. Tuazon J, Casalino D, Syed E, Batlle D. Lithium-associated kidney microcysts. Sci World J. 2008;8:828–9.Google Scholar
  59. Turan T, Eşel E, Tokgöz B, Aslan S, Sofuoğlu S, Utaş C, Keleştimur F. Effects of short- and long-term lithium treatment on kidney functioning in patients with bipolar mood disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:561–5.View ArticlePubMedGoogle Scholar
  60. Van Beneden K, Geers C, Pauwels M, Mannaerts I, Verbeelen D, van Grunsven LA, Van den Branden C. Valproic acid attenuates proteinuria and kidney injury. J Am Soc Nephrol. 2011;22:1863–75.View ArticlePubMedPubMed CentralGoogle Scholar
  61. Weinstein JR, Anderson S (2010) The aging kidney: physiological changes. Adv Chronic Kidney Dis 17(4):302-307View ArticlePubMedPubMed CentralGoogle Scholar
  62. Zaidan M, Stucker F, Stengel B, Vasiliu V, Hummel A, Landais P, et al. Increased risk of solid renal tumors in lithium-treated patients. Kidney Int. 2014;86:184–90.View ArticlePubMedGoogle Scholar


© The Author(s) 2017